Can I Work, Exercise, and Travel During CMML Treatment?
At a Glance
Many people with chronic myelomonocytic leukemia can continue working, exercising, and traveling during treatment, but plans should be adapted to fatigue, low blood counts, and infection or bleeding risks. Coordinate timing and safety precautions with your hematology team.
Yes, many people with chronic myelomonocytic leukemia (CMML) are able to work, exercise, travel, and maintain active lives during their treatment. However, because both CMML and its therapies—such as hypomethylating agents, targeted therapies, or stem cell transplants—affect your blood counts and immune system, you will likely need to adapt your routines. Planning ahead around fatigue, infection risks, bleeding risks, and your clinic schedule is essential for maintaining your quality of life.
It is normal to find these adjustments emotionally challenging. Consider bringing a partner or support person to your appointments to help plan how to maintain the activities most important to you.
Navigating Work and Daily Energy
CMML and treatments like venetoclax or azacitidine can cause significant myelosuppression (a decrease in blood cell production in the bone marrow), leading to anemia and fatigue [1][2][3]. To manage work and daily tasks:
- Request flexibility or support: If you are working, ask your employer about remote work options, flexible hours, or modified duties. Speak with a social worker about disability accommodations or medical leave if working becomes too difficult.
- Manage anemia: Anemia is assessed by measuring your hemoglobin level. To manage it, your care team may recommend red blood cell transfusions. For certain patients, depending on their CMML subtype and baseline levels, erythropoiesis-stimulating medicines might be used to help red cell production [4][5].
- Listen to your body: Build dedicated rest periods into your daily routine and prioritize your most demanding tasks for when you typically have the most energy.
Exercising Safely
Staying active is generally safe and encouraged during blood cancer treatment, as physical activity can improve walking capacity, preserve muscle strength, and boost your overall function [6][7]. However, you must exercise safely based on your current blood counts:
- Watch your platelets: Thrombocytopenia (low platelets) makes it harder for your blood to clot. While bleeding risk increases significantly when platelets drop below 25 × 10⁹/L [8], there is no single safe number for exercise. Restrictions depend on your symptoms, balance, and the type of exercise. Ask your team for personalized guidelines, and generally avoid contact sports or high-impact activities.
- Modify for anemia: If your hemoglobin is low, your heart and lungs have to work harder. Avoid pushing through shortness of breath, dizziness, or chest pain. Gentle exercises like walking or yoga are often best.
- Infection control: When your absolute neutrophil count (ANC) is low (neutropenia), you are at higher risk of infections [9]. Avoid sick contacts and crowded, poorly ventilated indoor spaces. Wash your hands frequently and clean shared exercise equipment.
Planning for Travel
Traveling with CMML requires careful coordination with your hematology team, especially if you are traveling during active treatment or after a stem cell transplant [10].
- Timing: Avoid remote or poorly supported travel during periods of expected severe cytopenias (when blood counts are very low) unless approved by your care team. If you have had an allogeneic stem cell transplant, travel may be highly restricted for months due to intense immunosuppression, graft-versus-host disease risks, and revaccination requirements [10].
- Vaccinations: Staying up-to-date on vaccines—such as those for influenza, COVID-19, and pneumococcal disease—is important. However, your body’s response may be weakened by treatments like venetoclax [11][12]. Always ask your team for timing. Standard flu and recombinant zoster (shingles) vaccines are non-live. Live vaccines are generally avoided during significant immunosuppression [11].
- Logistics: Confirm that your travel insurance covers pre-existing CMML, treatment complications, and medical evacuation. Pack your medications in their original containers in your carry-on luggage, bring extra doses, and carry a written medical summary with emergency contacts. Know how to identify an oncology-capable emergency department at your destination.
Intimacy, Sexual Health, and Fertility
Living a full life includes maintaining sexual health and intimacy, but treatment requires some precautions:
- Safety during low counts: Severe thrombocytopenia or active bleeding can make penetrative sexual activity unsafe. Ask your team for your specific platelet threshold.
- Medication exposure and infection: Some anticancer drugs can be present in sexual fluids. Furthermore, neutropenia increases your vulnerability to infections. Discuss with your team when condoms or barrier methods are required for STI prevention and to prevent drug exposure.
- Fertility and Pregnancy: Many treatments, including stem cell transplants and intensive chemotherapy, can impact fertility [13]. It is crucial to discuss sperm, oocyte, or embryo preservation with a specialist before starting treatment, as decisions are time-sensitive. Additionally, you must use effective contraception to avoid pregnancy during treatment due to the risks medications pose to a developing fetus.
🚨 When to Seek Emergency Care
Do not wait for a routine oncology callback for these symptoms. Seek immediate emergency care:
- Fever during neutropenia: This is a medical emergency [14]. Many centers define a fever as a single reading of 38.0°C (100.4°F) or higher [15], but always use the exact temperature threshold provided by your center.
- Severe bleeding: Uncontrolled bleeding, black or bloody stools, or vomiting blood.
- Neurologic symptoms: Sudden severe headache, confusion, or weakness (especially if your platelets are low).
- Cardiopulmonary symptoms: Chest pain, fainting, or severe breathlessness.
Common questions in this guide
Can I continue working during CMML treatment?
Is exercise safe while I am being treated for CMML?
Can I travel while receiving CMML treatment?
What blood count levels should change my activity plans?
When is a fever during CMML treatment an emergency?
Which vaccines are safe during CMML treatment?
Can CMML treatment affect fertility or sexual health?
Appointments are short. Make every minute count.
Specialist visits move fast. Let us help you prep so your time goes to what matters.
Work and daily energy
Could my employer offer remote work or flexible hours during treatment?
Safe exercise limits
What exercise limits should my team set based on my platelet counts?
Vaccines and timing
When should I get influenza, COVID-19, or pneumococcal vaccines during treatment?
Related questions
Show more
Get notified when new evidence is published on chronic monocytic leukemia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (15)
- 1
A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia.
Santini V, Allione B, Zini G, et al.
Leukemia 2018; (32(2)):413-418 doi:10.1038/leu.2017.186.
PMID: 28607470 - 2
Venetoclax-Based Regimens in Chronic Myelomonocytic Leukemia: A Systematic Review and Meta-Analysis.
Abdulgayoom M, Afana MS, Saleh LH, et al.
Acta haematologica 2026; 1-16 doi:10.1159/000551885.
PMID: 41945493 - 3
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study.
Garcia-Manero G, Griffiths EA, Steensma DP, et al.
Blood 2020; (136(6)):674-683 doi:10.1182/blood.2019004143.
PMID: 32285126 - 4
Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia.
Xicoy B, Germing U, Jimenez MJ, et al.
European journal of haematology 2016; (97(1)):33-8 doi:10.1111/ejh.12679.
PMID: 26341961 - 5
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update.
Bohlius J, Bohlke K, Castelli R, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(15)):1336-1351 doi:10.1200/JCO.18.02142.
PMID: 30969847 - 6
Safety, feasibility, and effectiveness of exercise interventions in patients with hematologic malignancy during chemotherapy: a systematic review and meta-analysis.
Luo Y, Ren Y, Li Y, et al.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2025; (33(8)):685 doi:10.1007/s00520-025-09748-4.
PMID: 40646359 - 7
Physical Characteristics Pertaining to Health-Related Quality of Life in Hospitalized Patients With Hematologic Malignancies: A Cross-Sectional Study.
Kofuji H, Aoyama T, Hishizawa M, Miyazaki H
Cureus 2025; (17(8)):e91063 doi:10.7759/cureus.91063.
PMID: 41018401 - 8
Treatment of chemotherapy-induced thrombocytopenia in patients with non-hematologic malignancies.
Kuter DJ
Haematologica 2022; (107(6)):1243-1263 doi:10.3324/haematol.2021.279512.
PMID: 35642485 - 9
Fungal Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patients.
Bays DJ, Thompson GR
Infectious disease clinics of North America 2019; (33(2)):545-566 doi:10.1016/j.idc.2019.02.006.
PMID: 31005138 - 10
Is it time to reconsider prophylactic antimicrobial use for hematopoietic stem cell transplantation? a narrative review of antimicrobials in stem cell transplantation.
Jahan D, Peile E, Sheikh MA, et al.
Expert review of anti-infective therapy 2021; (19(10)):1259-1280 doi:10.1080/14787210.2021.1902304.
PMID: 33711240 - 11
Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.
Kamboj M, Shah MK
Infectious disease clinics of North America 2019; (33(2)):593-609 doi:10.1016/j.idc.2019.02.007.
PMID: 31005140 - 12
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies.
Chung DJ, Shah GL, Devlin SM, et al.
Blood cancer discovery 2021; (2(6)):568-576 doi:10.1158/2643-3230.BCD-21-0139.
PMID: 34778797 - 13
Contemporary Risk Stratification and Treatment of Chronic Myelomonocytic Leukemia.
Tremblay D, Rippel N, Feld J, et al.
The oncologist 2021; (26(5)):406-421 doi:10.1002/onco.13769.
PMID: 33792103 - 14
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022.
Griffiths EA, Roy V, Alwan L, et al.
Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(5)):436-442.
PMID: 35545171 - 15
Real-world effectiveness of mecapegfilgrastim for prophylaxis in patients with breast cancer receiving 2-weekly and 3-weekly chemotherapy in China.
Shi Y, Fu P, Wang Y, et al.
BMC cancer 2026; (26(1)).
PMID: 42260418
This page is for informational purposes only and does not replace medical advice. Your hematology team should set personalized limits for work, exercise, travel, intimacy, vaccines, and emergency care based on your treatment and blood counts.